Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161100 | 0.87 | GRIN1 (0.35) | RORCGRIN1GRIN2B | |
| SCHEMBL20140411 | 0.82 | L3MBTL1 (0.46) | L3MBTL1PDE5A | |
| SCHEMBL24206019 | 0.81 | RORC (0.43) | RORCPDE5A | |
| SCHEMBL24205854 | 0.76 | PDE5A (0.37) | GRIN1GRIN2BSLC22A12PDE5A | |
| SCHEMBL20161103 | 0.76 | PDE5A (0.40) | GRIN1GRIN2BPDE5A | |
| SCHEMBL21787380 | 0.73 | L3MBTL1 (0.44) | L3MBTL1PDE5A | |
| SCHEMBL24205908 | 0.73 | L3MBTL1 (0.44) | L3MBTL1PDE5A | |
| SCHEMBL21787192 | 0.73 | ESR1 (0.46) | GRIN1GRIN2BPDE4APDE4BPDE4C | |
| SCHEMBL20140478 | 0.72 | ELANE (0.35) | GABRA1GABRA5GRIN1GRIN2BPDE4A | |
| SCHEMBL20161090 | 0.72 | PDE5A (0.39) | GRIN1GRIN2BPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | RORC 1918/4885GABRA1 1733/4885GABRA5 1755/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | RORC 1925/4885GABRA1 1796/4885GABRA5 1863/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | RORC 1918/4885GABRA1 1733/4885GABRA5 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.